Depression in late life: psychiatric-medical comorbidity by Katz, Ira R.
The links between late-life depression and the med-
ical comorbidities that are often associated with it
can be divided into two paths. The path from med-
ical illness to depression reflects general mechanisms
related to stress, disability, and loss, as well as more
specific physiological mechanisms, including those
related to subclinical cerebrovascular disease,
adverse drug effects, and endocrine/metabolic
effects. Similarly, the path from depression to med-
ical illness includes general mechanisms related to
self-neglect, decreased adherence to medical treat-
ments, maladaptive health-related behaviors, and,
possibly, more specific physiological mechanisms
including those related to altered endocrine and
autonomic functions. In the clinical context, these
two paths can interact to constitute a vicious cycle.
With further research, it should be possible to trans-
late current understanding in these areas into
advances in both basic knowledge and treatments
that could initiate virtuous cycles with beneficial
effects for both mental and physical health. 
he 1991 National Institutes of Health (NIH)
Consensus Statement on the Diagnosis and Treatment
of Late-Life Depression
1 noted that the hallmark of
depression in the elderly was its co-occurrence or
comorbidity with medical illness.The theme of comor-
bidity, the interaction between mental and physical
health in late life, has been one of the major areas of
recent research in geriatric psychiatry. In this,geriatrics
has led advances in an area of general importance.
Although the coexistence of medical illness and depres-
sion is less common in younger individuals,psychiatric-
medical comorbidity is important throughout the life
span;in fact,its impact may be greater in younger adults.
At this time, the most general conclusions from the
available literature must be that medical illness can be
both a cause and a consequence of depression,and that
treatment of depression, regardless of the clinical con-
text in which it occurs, can have a positive effect on
quality of life,functioning,and health.Moreover,current
knowledge in this area should serve to guide further
research to develop novel treatments,improve the effec-
tiveness of established treatments, and provide insight
into pathogenic mechanisms.
Psychiatric-medical comorbidity is important at several
levels. Pragmatically, it can affect the recognition, diag-
nosis, treatment, and delivery of care for patients with
depression.More conceptually,it can affect the mecha-
nisms responsible for the pathogenesis of depression
and for its impact as a multisystem disease.Among the
early findings that established geriatric psychiatry as an
important field of scientific inquiry were those of Sten-
stedt,
2 Hopkinson,
3 and Mendlewicz
4 demonstrating that
elderly patients with depression could be divided into
two subgroups, early-onset depressives, whose late-life
depression was a recurrence of a disorder that had its
initial onset earlier in life, and late-onset depressives,
for whom depression began for the first time in late life.
These groups differed in terms of family histories and
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81genetic risk for depression,with an excess of depression
among first-degree relatives for the early-onset depres-
sives. In contrast, the late-onset depressives had an
excess of other factors, especially chronic medical ill-
ness,suggesting that physical illness could play an impor-
tant role in the pathogenesis of those depressions that
occur for the first time in later life.
Although these findings have had an enormous impact
on subsequent research,identification of the path from
physical illness to depression represents only one of
the factors linking depression and medical illness.
Another body of work has demonstrated the impor-
tance of  the mirror image path, that proceeding from
depression to medical illness. In his prospective study
of a cohort of college students from the 1940s, Vail-
lant found that there was an association between
depression and chronic, disabling illnesses in his sub-
jects when they reached their seventies.
5 However,
contrary to what one may have expected, he found
that this association could be explained by the
increased incidence of chronic disease and disability
among those who, earlier in life, had exhibited evi-
dence of depression.This finding reinforces epidemi-
ological findings suggesting that patients with depres-
sion exhibit a higher subsequent incidence of diabetes
6
and an increased number of first myocardial infarc-
tions,
7-11 as well as clinical research findings that
women with depression experience an accelerated rate
of osteoporosis.
12 Also relevant may be findings sug-
gesting that a history of depression is a risk factor for
Alzheimer’s disease.
13,14
The research demonstrating the importance of depres-
sion as an antecedent of medical illness was conducted
in populations of aging rather than aged individuals.
Among the elderly, the most salient issues may not be
related to the initial incidence of either depression or
disabling disease,but,instead,to how existing disorders
affect each other.Evidence that established physical ill-
ness can affect the clinical course of depression comes,
for example, from observations that depression may be
more persistent among those patients with cardiac dis-
ease than several other chronic diseases,
15 and that it
may be more resistant to antidepressant treatment in
frail elderly patients for whom disabling medical ill-
nesses have led to protein-calorie malnutrition than
among individuals who are more fit.
16Viewing the paths
in the opposite direction, there is also evidence from
multiple sources that depression can affect the clinical
course of established medical illnesses by presenting
barriers to convalescence and recovery, increasing dis-
ability, cognitive impairment, pain, and related symp-
toms.
17 These findings can be summarized with the uni-
fying hypothesis that depression amplifies the morbidity
and disability associated with medical illnesses;they sug-
gest that the recognition and treatment of depression in
the presence of other medical illnesses can serve as a
form of secondary prevention that can decrease the
impact of these conditions.
18
Some recent studies have challenged the basic model of
Stenstedt, Hopkinson, and Mendlewicz. Lyness and
coworkers studied a sample of elderly patients hospi-
talized for depression and found comparable measures
of physical illness in those with early- and late-onset
disease.
19 Although their findings appear inconsistent
with earlier distinctions between early- and late-onset
depressions, it is important to note that more than a
generation elapsed between these studies, and that the
relative contribution of the path that extends from med-
ical illness to depression versus that which extends from
depression to medical illness may well vary over time as
a result of cohort effects,increases in longevity resulting
from changes in lifestyles and medical care, and
advances in the treatment of both medical and mental
illnesses.Another challenge to this model comes from
studies of patients with one specific type of comorbidity:
major depression as it coexists with Alzheimer’s dis-
ease. Here depression is, in fact, associated with an
excess of depression among first-degree relatives, sug-
gesting that depression in Alzheimer’s disease occurs
among those who are at increased genetic risk.
14,20-23
These findings suggest that the mechanisms linking
depression with other disorders may differ between
conditions, and that specific studies of the associations
between depression and commonly occurring comor-
bidities may be of value.
Studies of the mechanisms underlying the increases in
mortality associated with depression have also led to
apparent conflicts between findings.Investigations of
patients after myocardial infarction have consistently
found a robust association between depression and
decreased survival, which remains significant after
controlling for the severity of the underlying cardiac
disease.
23-26 However, findings in frail elderly patients
in nursing homes have been less consistent.Although
all investigations in this area have found that major
depression is associated with decreased survival,
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this can be attributed to depression itself or to the
associations of both depression and mortality with
more severe medical illness
27-29; differences between
studies may depend upon the nature of the control
groups and the methods that were used to control for
the extent of medical illness. More generally, one
might expect findings in this area to depend upon the
context and the population under investigation. In a
population such as patients with a recent myocardial
infarction,where depression may predispose patients
to sudden death, it may be relatively easy to test for
the extent to which depression directly contributes to
mortality. However, in other contexts, such as long-
term care populations, where depression may accel-
erate a more continuous pattern of deterioration and
decline leading to death, the analytic problems are
more complex. If one evaluated the mechanisms by
which depression increased mortality early in the
process, before it had led to significant deterioration,
one might find a direct effect of depression. Howev-
er, if one studied the same effects later during the
course of the patients’ illnesses,when depression had
already made a substantial contribution to decline, it
might no longer be possible to find effects of depres-
sion that would remain significant after controlling
for the severity of medical illness.This discussion sug-
gests that the mechanisms responsible for the conse-
quences of depression,as well as those responsible for
its causes, may differ between clinical settings and
comorbid conditions.
Although knowledge in this field has advanced primar-
ily through explorations of unidirectional models for
the links between mental and physical health in late
life, those interested in this area from a clinical, finan-
cial, or policy perspective should recognize that the
most valid models must be bidirectional. Depression
and medical illness in late life are linked through com-
plex reciprocal mechanisms in which pathology in one
domain can accelerate deterioration in the other.These
interactions can constitute a vicious cycle that can, in
some cases, begin early in life and end in premature
death. Recognition of these linked mechanisms is
important because of their implications for prevention
and treatment;recognition and treatment of depression
can initiate a virtuous cycle that may not simply
improve mental health and quality of life,but also pre-
vent physical decline.
Evaluating the associations between medical
illness and depression
As discussed above, observed relationships between
mental and physical health can depend upon the cohort
studied,the setting,and the population from which study
samples are drawn.Additional problems arise in studies
designed to investigate the associations of depression
with specific disorders and to evaluate underlying mech-
anisms.These arise because medical illnesses can lead to
depression through the additive or interacting effects of
a number of mechanisms. Some are general and are
associated with factors such as the experience of dis-
ability, pain, stress, loss, or impaired self-esteem as a
result of medical illness. Other more specific mecha-
nisms may involve disease-related structural abnormal-
ities in brain, or physiological abnormalities that affect
the brain or the periphery. Any observed associations
of depression with measures or correlates of physical
illness could reflect general as well as specific mecha-
nisms. Therefore, research must always include some
type of control for these nonspecific effects of disease.
Another complication occurs in case of concomitant
multiple disorders. Disabling chronic illnesses accumu-
late with aging such that middle-aged and “young-old”
individuals often suffer from a single disorder, but the
“old-old,” most often, suffer from many. Investigations
into the mechanism of association between mental and
specific diseases or physiological abnormalities in homo-
geneous populations of younger individuals are less
likely to be obscured by the presence of multiple,poten-
tially interacting abnormalities,but they may miss mech-
anisms that arise specifically out of such interactions.
Moreover, the problems associated with choosing con-
trol conditions are, perhaps, greatest in the presence of
multiple disorders. In probing mechanisms, the salient
questions are not whether specific disorders or abnor-
malities are associated with  depression, but whether
the associations remain significant after controlling for
general mechanisms. One strategy may involve use of
summary measures of comorbidity or illness burden that
rely upon clinical judgments or information available
from medical records. However, available instruments
differ in the dimensions of illness considered,and there
is no consensus as to what should be measured in rating
illness severity.An alternative approach may be to use
disability as a control measure.For example,in evaluat-
ing the theory that cerebral microvascular disease may
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to compare patients with hypertension and diabetes,dis-
orders that may lead to depression via such mechanisms,
with comparably disabled control subjects with
osteoarthritis,a disorder that may lead to depression by
primarily noncerebral mechanisms;however,such com-
parisons would be made difficult by differences between
disorders in the nature of the disability and their mean-
ing to the patients.
Experience from the University of Pennsylvania’s
National Institute of Mental Health (NIMH)-supported
Intervention Research Center provides an example of
the complexities involved in drawing conclusions about
the specificity of the associations between depression
and medical illness in geriatric populations.As described
previously,
30,31 this study evaluated residents (average
age 85 years) from a large urban nursing home and con-
gregate apartment facility at 2 weeks after their admis-
sion (or at the anniversary of their admission) with a
series of measures.For the findings summarized in Table I,
cognitively more intact individuals with a score on the
Blessed Information-Memory-Concentration Test less
than 13 were evaluated with a modified Schedule for
Affective Disorders and Schizophrenia (mSADS) inter-
view and the Geriatric Depression Scale (GDS) and
were classified at their initial interview and after 1 year
as euthymic,dysphoric (with persistent sadness or anhe-
donia on the mSADS or GDS score >10), or as experi-
encing a major depressive episode. Disability was eval-
uated using the Physical Self-Maintenance Scale (PSMS)
of Lawton and Brody. Medical comorbidity was evalu-
ated with the Cumulative Illness Rating Scale (CIRS),as
previously described
32;this scale uses clinician judgments
to measure the severity of disease in each of 13 systems
and 2 summary measures, the mean score across sys-
tems,and the number of systems with at least moderate
disease severity. For evaluating changes over a 1-year
period, subjects were considered to decline if they had
incident dysphoria or depression or if they worsened
from dysphoria to major depression.The study sample at
Basic research
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Indicator Correlation with Association with Association with
disability depression 1-year decline
(r; n=420-480) F (2, 478) F (1, 224)
PSMS – 65.098*** 4.423*
Mean CIRS 0.322** 12.347***(a) 2.553
No. of CIRS systems > mild 0.352** 8.284**(a) 2.480
Cardiac 0.159** 1.241 4.237*(a)
Hypertension -0.005 2.371 3.093
Vascular 0.168** 4.711**(a) 2.735
Respiratory 0.155** 2.132 0.280
EENT 0.102* 2.882 2.521
Upper GI 0.123* 3.739*(a) 0.341
Lower GI 0.022 5.573** 0.552
Hepatobiliary 0.089 4.372* 1.327
Renal 0.158** 1.171 2.820
Other GU 0.130** 0.539 1.694
Musculoskeletal 0.251** 1.517 1.169
Neurological 0.376** 6.796**(a) 0.922(b)
Endocrine/metabolic 0.124** 4.849 0.539
*P<0.05; **P<0.01; ***P<0.001. (a) no longer significant after controlling for disability; (b) significance emerges after controlling
for disability; Abbreviations: CIRS, Cumulative Illness Rating Scale; EENT, eye, ear, nose, and throat; GI, gastrointestinal; GU, geni-
tourinary;  PSMS, Physical Self-Maintenance Scale.
Table I. Associations between medical illness and depression in patients with Blessed IMC (Information-Memory-Concentration)
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baseline consisted of 480 individuals, 55.3% euthymic,
29.7% dysphoric, and 15.0% with major depression.
Over the 1-year period, the affective status of 27 of 226
subjects (11.9%) for whom follow-up data were avail-
able,declined.
As shown in Table I, depression was associated with
summary measures of physical illness and with disability.
Among the systems probed, there were associations of
depression with vascular disease,upper gastrointestinal
disease,lower gastrointestinal disease,hepatobiliary dis-
ease,neurological disease (primarily stroke and parkin-
sonism) and endocrine-metabolic disease (primarily dia-
betes). However, after controlling for disability, the
associations with summary measures of medical illness
were no longer statistically significant,and the only asso-
ciations between depression and disease in specific sys-
tems were those with lower gastrointestinal and
endocrine-metabolic systems.In stepwise logistic regres-
sion models that considered the systems that had uni-
variate associations with depression, any depression
(dysphoria or major) was found to be associated (model
χ
2=19.292; P=0.0002) with upper and lower gastroin-
testinal and neurological disease, while major depres-
sion was associated (model χ
2=17.72; P=0.0005) with
lower gastrointestinal, neurological, and endocrine-
metabolic disease. After controlling for disability, any
depression was associated (χ
2=5.471; P=0.0193) only
with upper gastrointestinal disease,while major depres-
sion was associated (χ
2=11.909, P=0.0026) with lower
gastrointestinal and endocrine-metabolic disease.
Higher levels of disability and cardiac disease at the ini-
tial assessment were associated with worsening of affec-
tive status over a 1-year period.However,after control-
ling for disability, the association between cardiac
disease and worsening depression was no longer signif-
icant, and a new association between neurological dis-
ease and worsening depression emerged. In contrast,
none of the variables tested was associated with persis-
tence versus improvement over a 1-year period in those
who were depressed at their initial assessments.
This discussion demonstrates that the specific rela-
tionships observed between mental and physical
health can depend strongly upon the assumptions and
methods used in analyses. From a broad and prag-
matic perspective, the findings on the baseline asso-
ciations between depression and endocrine-metabolic
disease and between cardiac disease and worsening
of depression over a 1-year period are compatible
with models suggesting a relationship between
depression and vascular risk factors.The findings on
gastrointestinal disease are similar to those found by
Zubenko and colleagues in a psychiatric inpatient
setting,
33 and suggest the salience of autonomic
effects (see below). More critically, however, the
results of analyses that control for disability empha-
size the principle that findings can depend critically
upon methodology.
Medical illnesses as causes for depression:
specific mechanism
Vascular mechanisms
As summarized by Alexopoulos and colleagues,
34 a
growing body of recent research has focused on cere-
brovascular mechanisms for the onset of late-life
depression. This line of investigation began with the
empirical findings by Coffey and others
35 that late-life
depressives, most often those with late-onset disease,
exhibited an excess of subcortical and deep white mat-
ter hyperintensities on magnetic resonance imaging
(MRI) scans, consistent with the hypothesis that
depression in late life could be a manifestation of sub-
clinical cerebrovascular disease. The accumulating
findings allowed both Alexopolous and his cowork-
ers
36,37 and Krishnan and his colleagues
38 to propose that
vascular depression may be a specific subtype of late-
life depression that could be defined either in terms of
MRI findings or the presence of specific medical
comorbidities;they also suggested that clinical features
associated with vascular depression might include
increased anhedonia, psychomotor retardation, and
loss of insight, but decreased agitation and guilt.
Although evidence that cerebrovascular mechanisms
can account for a significant component of the depres-
sions that arise in late life is accumulating,a number of
questions remain,primarily about the specificity of the
associations.
From a formal perspective, it is important to question
whether the MRI findings associated with depression
are, in fact, directly involved in its pathogenesis or
whether they are an indirect index of the severity of
underlying diseases that could lead to depression
through other paths. Other questions about specificity
follow from empirical findings.These include questions
about the nature of the lesions based upon observa-tions that comparable MRI findings can occur in
younger and physically healthier patients with bipolar
disease.
39,40 Moreover,Lyness and coworkers reported a
lack of association between cerebrovascular risk fac-
tors and depression in a comparison of psychiatric inpa-
tients with normal controls.
41 Finally, although Kumar
and colleagues reported an association of depression
with subcortical and deep white matter hyperintensi-
ties,and have used regression models to demonstrate a
path from physical illness through MRI findings to
depression, they were not able to relate the MRI find-
ings specifically to disorders associated with increased
risk for cerebrovascular disease rather than more gen-
eral measures of medical illness burden.
42 Interestingly,
in addition to these findings, they found independent
associations of depression with measures of cerebral
atrophy,suggesting that depression may result from sep-
arable vascular and neurodegenerative mechanisms.
Other questions relate to the specificity of the effects
of MRI findings.As might be expected from electroen-
cephalographic findings that the relevant lesions can dis-
rupt interconnections between cortical areas,
43 there is
evidence that they can be associated with multiple forms
of morbidity, including disturbances of gait and bal-
ance
44,45 and cognitive deficits,
46 especially deficits in exec-
utive functions, as well as depression. These findings
raise questions about whether the association between
MRI lesions and depression is a direct effect or an indi-
rect manifestation of disability or dysfunction related
to other effects.
The suggestion that vascular depressions are associated
with symptoms consistent with frontal system deficits,
and the observed association of MRI lesions with exec-
utive deficits suggests the need for further studies on
the diagnosis of late-life depression. Although the dif-
ferential diagnosis of depression and dementia has
received extensive attention in both the research and
the practice literature, there has been little discussion
about the overlap or distinction between depression and
frontal lobe syndromes.The association between vascu-
lar pathology and executive deficits together with evolv-
ing questions about the associations of both with depres-
sion suggest the importance of research designed to
optimize the discrimination between these syndromes
and to ensure that observed associations are not inflated
by confounding of case identification.
There have been proposals about the neuroanatomic
circuits that may be the substrate for the pathogenesis
of depression in individuals with subcortical and deep
white matter hyperintensities on MRI scans,
47 and there
have been preliminary attempts to map the relevant
lesions.
48 It is possible that larger-scale studies that map
the MRI-located lesions in vulnerable patients with
and without depression may be informative about the
neuroanatomic basis for vascular depressions. How-
ever, before such studies can be designed, it will be
necessary to obtain further information on the nature
of the association between brain lesions and depres-
sion.Mapping may be straightforward if the association
between depression and strategically placed lesions is
direct, immediate, and inevitable. However, mapping
would be more complex if vascular depression
occurred within a biopsychosocial matrix in which
patients with significant lesions were at increased risk
for depression,but where stress and loss still act as pre-
cipitants for the onset of depressive episodes,and social
support still acts as a buffer.
The concept of vascular depression has already been of
value to the field of psychiatry by stimulating research
and critical thinking in the area of psychiatric-medical
comorbidity. Given the complexity of the problem and
the limitations in available methods for research in
accessible patient populations, the next steps in devel-
oping this model should, perhaps, be pragmatic.
Research on vascular depression has,thus far,suggested
the importance of advancing the differential diagnosis of
depression and frontal lobe syndromes in elderly and
medically ill patients.Studies of the mediators and mod-
erators of the associations between depression,risk fac-
tors for cerebrovascular disease,and depression are also
important. Although such studies will be necessary to
allow the design of mapping experiments as described
above,their more immediate value may be in determin-
ing the extent to which there may be individuals with
vascular lesions or risk factors without current mood
disorders who may be at high risk for depression, and
who may benefit from preventive interventions. The
most critical next step, however, may be to confirm and
follow up on early findings that suggest that vascular
depressions may be associated with differential responses
to specific treatments.
49
Drug toxicity
The risks and costs of adverse drug effects in the elder-
ly were emphasized in a 1995 General Accounting
86
Basic researchOffice report.
50 The literature on psychiatric side effects
was comprehensively reviewed in a book by Brown and
Stoudemire
51 and the problem from a lay and personal
perspective was described by Fried.
52 One indication of
the scope of the problems can be provided by review of
the medications discussed as potential causes of depres-
sion within the current literature. Table II summarizes
those agents discussed in papers indexed in MEDLINE
over the past 10 years under the headings “depression”
or “depressive disorder”and the subheading “chemical-
ly induced.”An estimate of the significance of adverse
drug effects as causes of depression can be derived from
the work of Patten and coworkers
53 who studied a series
of medical inpatients for association between the inci-
dence of depressive symptoms and prescription of any
of six classes of medications (β -blockers, histamine H2
receptor blockers, corticosteroids, sedative hypnotics,
calcium-channel blockers, and angiotensin-converting
enzyme inhibitors) and reported that 56% of the
depressive symptoms occurring in the population could
be attributable to use of these agents.Although this esti-
mate is provocative, it must be viewed with caution.As
with the other potential pathogenic mechanisms, the
study of adverse drug effects must control for potential
biases; most important may be the possibilities of con-
founding by indication, where the apparent relation-
ships of medications with symptoms may,in fact,reflect
associations with the disorder that is being treated,
rather than a true adverse drug effect.A recent critical
review
54 summarized this area by noting that most of the
literature consisted of case reports, and that there were
relatively few empirical studies. Nevertheless, it con-
cluded that corticosteroids, certain calcium-channel
blockers,and digoxin have been associated with depres-
sion by replicated,well-conducted studies.In addition,it
suggested that the literature is sufficient to warrant sus-
picion about antihyperlipidemic agents, angiotensin-
converting enzyme inhibitors, sedative hypnotics, psy-
chostimulants, and certain hormonal agents. It
concluded that the potential association between 
β -blockers and depressive symptoms remains contro-
versial, and that there was no substantial evidence that 
L-dopa or histamine H2 receptor blockers cause depres-
sion. Clearly, this is an area in which further research is
needed.
Historically,this area has been dominated by research
related to biogenic amine theories of depression as a
conceptual model. The suggestion that medications
that affect aminergic systems can cause depression was
key to the development of these theories of depression
almost two generations ago. Nevertheless, the empiri-
cal evidence in support of these associations remains
marginal.Although the suggestion that reserpine can
cause depression is now primarily of historic interest,
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Anticonvulsants
Phenobarbital
Phenytoin
Topiramide
Vigabatrin
Antihyperlipidemic agents
Antiparkinsonian agents
Cardiovascular agents
Angiotensin-converting enzyme inhibitors
β -Blockers
Calcium-channel blockers
Clonidine
α -Methyldopa
Hormonal treatments
Anabolic steroids
Contraceptive agents (oral and depot)
Corticosteroids
Gonadotropin-releasing hormone antagonists
Progesterone
Tamoxifen
Migraine treatments
Cinarizine
Flunarizine
Oxetorone
Sumatriptan
Others
Antipsychotic agents
Baclofen
Benzodiazepines and sedative hypnotics
H2-blockers
Interferon
Metoclopramide
Nonsteroidal anti-inflammatory drugs
Ofloxacin
Ondansetron
Psychostimulants
Retinoids
Tramadol
Table II. Medications discussed as possible causes of affective toxicity;
1989-1999.it is still important to take a critical perspective and to
ask whether reports of this association were adequate
in distinguishing between depression and extrapyra-
midal symptoms. Recent reviews agree that the evi-
dence to support the hypothesis that β -blockers can
cause depression remains controversial.
54,55 More gen-
erally,the vascular depression hypothesis,with its sug-
gestion that hypertension can itself be a risk factor
for depression, raises questions about whether any
apparent associations between depression and rele-
vant antihypertensive medications may an example of
indication bias,with symptoms related to the sequelae
of hypertension rather than to the direct effects of
medication.
In the absence of any well-established laboratory mark-
ers, animal models, or models of pathogenesis that
could serve as a basis for screening, the only way to
approach this area is through empirical research in
patient populations.Those adverse drug effects that are
most common, most acute, and most severe may be
identified during the process of drug development.
Most side effects, however, are identified only after
medications are approved for use. The sensitivity for
the detection of adverse effects of drugs used in clinical
practice depends strongly upon the base rate of the
symptoms in the population at risk.In general,the high
rates of depression in patients who require treatment
for medical illnesses will make it difficult to detect the
medication-related depressions. One exception, where
depression as a possible drug side effect was identified
through direct clinical observation,may be with thera-
peutic use of interferon,where the frequency of severe
depression temporally related to treatment has sug-
gested a specific effect.
56,57 More representative may be
suggestions of an association between depression and
the use of cholesterol-lowering drugs and angiotensin-
converting enzyme inhibitors,where suggestions about
toxicity developed from epidemiological studies. For
the former, concerns about depression and other psy-
chiatric side effects developed out of research showing
that,although reductions in cholesterol levels were not
associated with decreases in all-cause mortality, they
were accompanied by fewer cardiovascular deaths but
more deaths related to accidents and self-injury.
58 For
the latter, suggestive findings include those derived
from prescription asymmetry studies,in which the order
of prescribing antidepressants and the target drug are
evaluated as an approach for controlling for confound-
ing by indication.
59 The hypothesis that angiotensin-
converting enzyme inhibitors may cause depression
may appear surprising in light of earlier reports that
hypertensives treated with such agents exhibited better
quality of life than those treated with other agents such
as  -methyldopa.
60 This suggests another possible con-
found. On the basis of earlier research, practitioners
may have believed that angiotensin-converting enzyme
inhibitors were less likely to cause depression than
other agents, and may have been biased to prescribe
them preferentially to patients at increased risk for
depression;this,in turn,could have led to spurious asso-
ciations in subsequent studies.
Oslin has described a pilot study of a method that eval-
uates the effects of medications on the day-to-day vari-
ation of positive and negative affects in normal volun-
teers;inclusion of such measures in early clinical trials of
the safety of new drugs could, in principle, improve the
sensitivity for the early detection of affective toxicity.
61
However, a more general method for identifying the
medications that may cause depression may be through
studies of the associations between medication use and
observations or records of psychiatric symptoms,subse-
quent prescription of psychotherapeutic medications,or
use of mental health services. One beneficial effect of
the increasing organization of health care systems may
be the development of additional sources of data for
such studies. However, beyond the initial identification
of agents that may cause depression,it will be necessary
to control for potential confounding factors and to esti-
mate effect sizes before it is possible to use pharma-
coepidemiological findings either to guide clinical prac-
tice or to provide insight into pathogenic mechanisms.
Hormonal and cytokine-mediated mechanisms
There is an extensive literature suggesting associations
between even mild or subclinical hypothyroidism and
the pathogenesis of depression and decreased responses
to antidepressant medications.
62,63 Recently,Seidman and
Walsh have reviewed evidence that decreased testos-
terone activity in hypogonadal men may lead to depres-
sive symptoms.
64This,together with earlier findings sug-
gesting that decreases in testosterone in aged men were
most marked in those with chronic disease and disabil-
ity,
65 suggests that decreased androgen levels may medi-
ate some of the behavioral and affective changes asso-
ciated with medical illness in late life.
88
Basic researchThere has also been interest in the possibility that depres-
sion and related symptoms in patients with medical ill-
ness may be mediated via the neuropharmacological
effects of inflammatory cytokines such as interleukin -1β ,
tumor necrosis factor   (TNF- ), and interleukin-6.At
present, however, knowledge in this area is relatively
rudimentary. Current research on Alzheimer’s disease
is investigating the possibility that intracerebral inflam-
mation may play a role in initiating or maintaining the
process of neurodegeneration.
66,67Although some studies
have found measures of inflammatory activity or
increases in the activity of proinflammatory cytokines
in the periphery, the pathological processes associated
with the progression of Alzheimer’s disease are pre-
sumed to be operative within the brain. Theories of
inflammatory processes in Alzheimer’s disease have
stimulated research on the possible therapeutic or pre-
ventive effects of corticosteroids and nonsteroidal anti-
inflammatory drugs, including recently developed
cyclooxygenase (COX) 2 inhibitors.
Hypotheses about depression are less developed, and
more divergent.Maes has proposed that dysregulation
of immune and inflammatory processes may be basic
components of the pathophysiology of depressive dis-
orders.
68-71They have reported that apparently healthy,
mixed-age adults with depression exhibit evidence for
increased cytokine-mediated activities and for the acti-
vation of acute-phase processes.They probed the inter-
actions between cytokine systems and the hypothala-
mic-pituitary-adrenal axis (HPA), and suggested that
increased cytokine activities may drive the HPA axis
and may underlie the hypercortisolemia found in sub-
populations of patients with depression.Most basically,
the central element of their hypothesis is that the
increased cytokine activity and the activation of acute-
phase or inflammatory processes in depression is a reg-
ulatory abnormality characteristic of depression,rather
than a reflection of medical illness.
An alternative hypothesis for a role of cytokines in the
pathogenesis of depression is based upon concepts of
“sickness behavior.”
72-75 According to these models,
infection, inflammation, or tissue injury can activate
inflammatory processes and induce cytokines that can
act locally or systemically to regulate homeostatic
responses.Some of these responses,including those that
involve acute-phase processes, occur in the periphery,
while others involve (direct or indirect) actions of
cytokines on the central nervous system.Some of these
central nervous system–mediated effects,such as fever,
are physiological,while others are behavioral.The latter
include a number of nonspecific behaviors associated
with illness and injury such as decreased exploratory
activity,decreased sexual activity,anorexia,and changes
in sleep structure.Studies of the behavioral pharmacol-
ogy of the cytokines in experimental animals demon-
strate that they can,in fact,cause these behaviors;how-
ever, questions remain about the mechanisms through
which the induction of cytokines in the periphery can
cause centrally mediated effects. Nevertheless, this
hypothesis proposes that depression can occur when
cytokine-mediated processes are induced  by illness or
injury,and that the depressions that arise through these
mechanisms are pathological variants of normal and
adaptive sickness behaviors.
As discussed above, it is possible to distinguish
between two distinct cytokine-related theories of
depression, one in which the induction of cytokines
occurs spontaneously as a result of regulatory deficits
intrinsic to the depressive illness, and the other in
which they arise in the context of medical illness.
These models may, however, be poles in a continuum.
For example,cytokine-mediated processes initiated by
illness could, in principle, remain activated after ill-
ness as a result of a failure in restorative mechanisms.
Alternatively, regulatory abnormalities may allow for
the extensive induction of cytokines by minor illness
or injury. Thus, it is possible to propose a series of
plausible cytokine theories of depression.The impor-
tant question is, of course, whether there is empirical
evidence to support any of them.
Observations from our center that depressions associated
with high levels of disability and low levels of serum albu-
min (a negative-acute phase reactant as well as a marker
for protein-calorie nutritional status) constituted a treat-
ment-relevant subtype of depression less likely to respond
to nortriptyline treatment than other depressions, led us
to investigate the sickness behavior hypothesis in the
long-term care setting. Thus far, however, our findings
have been negative. The low serum albumin in depres-
sion appears to be a marker for subnutrition rather than
for acute-phase processes. Moreover, pilot studies (n=36
to 60) have found a modest association between plasma
levels of TNF-  and self-reports of appetite loss, but no
relationship between plasma levels of TNF- ,interleukin-
1β , or interleukin-6 and measures of depression. Thus,
our findings on appetite disturbances are consistent with
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the hypothesis that cytokine-associated sickness behavior
can occur in an elderly chronic care populations,but our
data do not support the suggestion that this mechanism
can explain a significant component of the depressions
seen in this population. Had these exploratory studies
found correlations between cytokine activities and
depression,it would have been necessary to conduct fur-
ther studies to determine if the cytokines were directly
associated with the affective and behavioral symptoms
or whether they were indirect measures of the severity of
illnesses that led to depression through other mecha-
nisms; however, in the absence of correlational findings,
questions about mechanisms are not relevant.
A recent report by Dentino and colleagues
76 provided
additional insight into this area.In a large-scale study of
1732 elderly individuals (mean age 77.6 years) living in
the community,they found a statistically significant cor-
relation (Spearman r=0.06) between log-transformed
plasma levels of interleukin-6 and measures of depres-
sion.Subsequent regression analyses demonstrated that
this effect remained significant in models that consid-
ered other biological variables, measures of self-care
deficits, and self-rated health. Unfortunately, although
this study found an association between depression and
stroke,a history of fracture,and arthritis,and an earlier
report of research on this study sample
77 found associa-
tions between plasma levels of interleukin-6 and cancer,
heart attack, and high blood pressure, this report did
not control for medical comorbidities.Thus,this report
does not allow the distinction between models in which
the association of depression and interleukin-6 is a
reflection of their common links with medical illness,
and those in which it arises independently.
The most significant conclusions from the work of
Dentino et al,
76 however,may follow from the quantitative
findings reported.The magnitude of the observed corre-
lation coefficient indicates that less than 0.4% of the vari-
ance in depression in the population can be attributed to
variability in (log-transformed) interleukin-6 levels.Thus,
this report demonstrates that interleukin-6–related mech-
anism can account for,at most,a small component of late-
life depressions. Although these mechanisms cannot
explain a substantial proportion of the late-life depres-
sions that occur in the community,the statistically signif-
icant correlations may provide a rationale for further
studies in specific populations in which the associations
may be more robust. However, even in such settings,
plasma levels of circulating cytokines may not be a sensi-
tive indicator of relevant processes.Furthermore,it would
be difficult for observational studies to distinguish
between direct effects of cytokines and correlations that
may occur because both depression and cytokine-related
processes arise from illness.Therefore,the most rigorous
research in this area,as well as the most clinically relevant,
may be to test pharmacological treatments that target
cytokine-related mechanisms for depression and related
behaviors in carefully selected patient populations.
Depression as a cause of medical illness
The mechanisms leading from depression to the onset
or worsening of medical illness are as complex as those
operative in the other direction. Here too, observed
effects may be related to both general and specific mech-
anisms. General mechanisms can include the effects of
self-neglect, poor nutrition, agitation, decreased physi-
cal activity, and lack of adherence with treatments
required for medical conditions. Other mechanisms can
be related to the sleep disturbances that occur as com-
ponents of depression, and the association between
depression and cigarette smoking.
78 One specific physio-
logical mechanism proposed to account for the excess of
osteoporosis in middle-aged women with depression is
related to the effects of hypercortisolemia.
12,79There have
also been preliminary suggestions that hypercortisolemia
and dysregulation of the HPA axis in depression may
lead to cerebral atrophy.
80,81Although hypercortisolemia
could, in principle, lead to immune dysfunction,
decreased carbohydrate tolerance, and muscle atrophy,
there is no consistent body of evidence to suggest that
such effects are operative in individuals with depression.
There have also been proposals that depression-related
changes in platelet activity
82,83 and heart rate variability
84,85
may be associated with the increased incidence of
ischemic heart disease in patients with depression and
with depression-related increases in mortality after
myocardial infarction.The decreased heart rate variabil-
ity in depression may be related to decreased parasym-
pathetic (vagal) tone; similar decreases in parasympa-
thetic activity could also account for the association of
depression with gastrointestinal disease.
86
It has been well established that a sizable subset of
patients with depression exhibit hypercortisolemia.
Although there appears to be significant variability in
the extent to which this normalizes with treatment and
the remission of depressive symptoms, there must still
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be questions about the extent to which this heterogene-
ity is characteristic of subtypes of depression or the
effects of different treatments.The associations of depres-
sion with decreased heart rate variability and decreased
parasympathetic tone are not as well established.
Although it is known that treatment with anticholinergic
tricyclic antidepressants can increase these effects,there
are questions about the impact of other treatments on
autonomic functions.
A critical unanswered question for psychiatric research
is whether the treatment of depression improves health
outcomes. It would clearly be difficult to conduct the
large-scale, long-term treatment studies with medical
outcomes that would be needed to address this issue
most directly.Intermediate goals,based upon the above
considerations, may be to explore the extent to which
measures of cortisol production and parasympathetic
activity could serve as proxy measures for health out-
comes in more accessible, shorter-term treatment stud-
ies.Although it is always necessary to be cautious about
the interpretation of proxy outcome data, such studies
could serve heuristic, hypothesis-building functions
about the extent to which health outcomes might differ
as a function of alternative treatments for depression,or
as a function of variations in duration and intensity
within treatments.
Conclusion: psychiatric medical comorbidity 
as a focus for translational research
Clinical studies on the association between depression
and medical illness can guide translational research.
Clinical studies of the paths leading from medical ill-
ness to depression could translate into larger-scale stud-
ies of prevention and treatment effectiveness in specific
patient populations.They could also translate into more
basic studies.The classic findings that chronic medical ill-
ness represents a path to depression that is separable
from genetic mechanisms suggests that findings from
studies on comorbidity will be needed to complement
anticipated findings from genetics to provide a compre-
hensive picture of the mechanisms that can lead to
depression.The most important results from studies on
the paths from depression to medical illness may be
translation into prevention research on the extent to
which treatment of depression can preserve health and
prevent the accelerated physical decline that is increas-
ingly being identified as a consequence of depression.❏
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Depresion en la edad avanzada : 
la comorbilidad medico-psiquiatrica
La relación existente entre la depresión en la edad
avanzada y las comorbilidades médicas, que a
menudo se asocian entre sí, pueden considerarse en
dos sentidos. La vía que va desde la enfermedad
somática a la depresión refleja mecanismos generales
vinculados al estrés, la incapacidad consiguiente y la
vivencia de pérdida, así como mecanismos más
específicos que comprenden a aquellos relacionados
con la enfermedad cerebrovascular subclínica,efectos
adversos de los fármacos, y efectos endocrinos y
metabólicos. Del mismo modo, la vía que conduce de
la depresión a enfermedades médicas incluye mecan-
ismos generales vinculados al descuido de sí mismos,
al progresivo desinterés en el cumplimiento con el
tratamiento médico, a conductas inadecuadas con
respecto a la propia salud, y posiblemente mecanis-
mos fisiológicos más específicos que se relacionan
con funciones autonómicas y endocrinas alteradas.
En el contexto clínico, estas dos vías pueden interac-
tuar constituyendo un círculo vicioso. Investigaciones
adicionales posibilitarían la transposición de la com-
prensión acutal en estas áreas en progresos tanto en el
campo de los conocimientos básicos como en el de los
tratamientos,pudiendo generar círculos virtuosos con
efectos benéficos tanto en la salud mental como fisica.
La dépression du sujet âgé : 
comorbidité médicale et psychiatrique
Les liens entre la dépression du sujet âgé et les comor-
bidités médicales qui lui sont souvent associées peu-
vent être séparés en deux voies. La première d’entre
elles, qui établit un lien entre la maladie somatique et
la dépression,est le reflet de mécanismes généraux qui
ont trait au stress, à l’incapacité et à la perte d’une
fonction ou encore de mécanismes plus spécifiques
incluant tous ceux qui ont un rapport avec une ma-
ladie cérébrovasculaire infraclinique, les effets indési-
rables des médicaments, mais aussi  des phénomènes
endocriniens ou métaboliques. De façon identique, la
seconde voie qui va de la dépression à la maladie so-
matique inclut des mécanismes généraux qui sont liés
à l’autodépréciation, à la diminution de l’observance
des traitements médicaux et à l’existence de comporte-
ments inadaptés,tributaires de l’état de santé.Elle peut
aussi inclure des mécanismes physiologiques plus spé-
cifiques qui intègrent ceux témoignant d’altérations
des fonctions endocriniennes et de l’autonomie. Dans
ce contexte clinique,ces deux voies peuvent constituer
un cercle vicieux. De futures recherches devraient
permettre de convertir des données disponibles dans
ces domaines en avancées aussi bien dans le domaine
de la recherche que dans celui des traitements avec, à
terme, la création de cercles vertueux capables
d’améliorer santé physique et mentale.
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